戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 an inhibitor of myosin function (butanedione monoxime).
2 ersed by addition of 10 mM 2,3-butanedione 2-monoxime.
3  and by the myosin inhibitor 2,3-butanedione monoxime.
4 yosin by cytochalasin D or 2,3-butanedione-2-monoxime.
5 ncreases were not blocked by 2,3-butanedione monoxime.
6 ng) were estimated by use of 2,3-butanedione monoxime.
7 s reversibly reduced by 5-mM 2,3-butanedione monoxime, a known cross-bridge inhibitor.
8 ly inhibited a slow phase, while butanedione monoxime, a myosin ATPase inhibitor, inhibited both the
9 on in the presence of 7.5 mM 2,3-butanedione monoxime, an inhibitor of actin-myosin cross-bridge cycl
10                         The drug butanedione monoxime, an inhibitor of myosins, blocked the accumulat
11 thase kinase 3 (GSK3) inhibitor indirubin-3'-monoxime and GSK3beta short interfering RNAs, demonstrat
12                              3) Butane-dione-monoxime and NH4Cl chloride affected contractile functio
13 esponse was affected by both 2,3-butanedione monoxime and sarcomere length in the same manner as acti
14 rs monoisonitrosoacetone and 2,3-butanedione monoxime and shows potential for further refinement.
15  slope of the restitution relation (diacetyl monoxime and verapamil) prevent the induction of VF and
16                             ADE, butanedione monoxime, and NP were given for cardioprotection before,
17         The addition of 3 mm 2,3-butanedione monoxime at pCa 9.0 showed that there was approximately
18 enosine triphosphatase using 2,3-butanedione monoxime (BDM) and found that phagocytosis was inhibited
19  cells (OHCs) while applying 2,3-butanedione monoxime (BDM) by pressure.
20 h 0.5 mM AlF4- or with 30 mM 2,3 butanedione-monoxime (BDM) during measurements of the Ca2+ dependenc
21                              2,3-Butanedione monoxime (BDM) is widely believed to act as a chemical p
22  of the chemical phosphatase 2,3-butanedione monoxime (BDM) on glycine current (IGly) of murine ventr
23  activated eggs treated with 2,3-butanedione monoxime (BDM) undergo a dramatic large-scale torsion, w
24  was conducted to evaluate 2,3-butanedione 2-monoxime (BDM), a compound that interferes with acto-myo
25 ing 20 nM dopamine, dopamine+2,3-butanedione monoxime (BDM), a MgATPase-inhibitor, or the calcium-sen
26 s of a chemical phosphatase, 2,3-butanedione monoxime (BDM), on endogenous and expressed Ca2+ channel
27     The myosin ATPase inhibitor, butanedione monoxime (BDM), reversibly inhibited gliding motility ac
28 (pCa 4.5) exposed to 10 mM 2,3-butanedione 2-monoxime (BDM), stretch was accompanied by a lattice com
29 ere insensitive to 5-10 mM 2,3-butanedione 2-monoxime (BDM), which inhibited active contractions.
30 al uncoupling drugs, such as 2,3-butanedione monoxime (BDM).
31 myosin-specific inhibitor, 2,3-butanedione 2-monoxime (BDM).
32 mol/L egtazic acid; 3) 5 mmol/L butane-dione-monoxime (BDM); or 4) 50 mmol/L ammonium chloride (NH4Cl
33 investigation was to utilize 2,3-butanedione monoxime (BDM; an inhibitor of contractile activation) t
34 treatment with cytochalasin D or butanedione monoxime blocks the streaming motion.
35 idodiacetyl reaction between 2,3-butanedione monoxime (diacetylmonoxime) and the de novo carbamido co
36 rch addresses the preparation of naphthalene monoxime hydrazide-hydrazones by traditional and innovat
37 viously that the small molecule indirubin-3'-monoxime (I3MO) prevents vascular smooth muscle cell (VS
38 ddition of the neutral oxime 2,3-butanedione monoxime increases the rate of reactivation of hCE1 from
39 tochalasin D) and myosin ATPase (butanedione monoxime), indicating that they rely on an actinomyosin
40  known antiangiogenic activity, indirubin-3'-monoxime (IRO), was identified.
41  the cardioplegic agent BDM (2,3-butanedione monoxime), its effects on the force-velocity properties
42 rates with myosin inhibitors 2,3-butanedione monoxime or KT5926 caused the reduction of both vinculin
43    Cross-bridge inhibition (with butanedione monoxime) or augmentation (with 2 deoxy-ATP) had no grea
44 concentrations of phosphate, 2,3-butanedione monoxime, or adenosine triphosphate at a fixed calcium c
45 he myosin ATPase inhibitor 2,3-butanedione-2-monoxime perturbed NF translocation within NB2a/d1 axona
46 ubation with the GSK3 inhibitor indirubin-3'-monoxime protected against this decrease in activity.
47 structures of a CNS-penetrating reactivator, monoxime RS194B, reversibly bound to native and venomous
48 , genistein, wortmannin, and 2,3-butanedione monoxime-sensitive pathway and replicated within phagoly
49                   Lapatinib and indirubin-3'-monoxime showed moderate hCOX-1 activity (19.5% and 28%
50 azapine, cytochalasin D, and 2,3-butanedione monoxime significantly inhibited (P < 0.05) in vitro inf
51 ed by the myosin inhibitor 2,3-butanedione-2-monoxime, suggesting that tension promotes tyrosine kina
52 abolished in the presence of 2,3-butanedione monoxime, suggesting that the basal level of contractile
53 nce of the tension inhibitor 2,3-butanedione monoxime suggests that regulatory light chain (RLC) phos
54 oss-bridge (inorganic phosphate, butanedione monoxime, trifluoperazine, and blebbistatin) are modifie
55 02190, RO-316233, GW786460X and indirubin-3'-monoxime were tested against human COX-1.
56 ng crossbridge inhibition by 2,3-butanedione monoxime when near-neighbour thin filament RU interactio